HRP970565B1 - Process for the crystalization of losartan - Google Patents

Process for the crystalization of losartan

Info

Publication number
HRP970565B1
HRP970565B1 HR970565A HRP970565A HRP970565B1 HR P970565 B1 HRP970565 B1 HR P970565B1 HR 970565 A HR970565 A HR 970565A HR P970565 A HRP970565 A HR P970565A HR P970565 B1 HRP970565 B1 HR P970565B1
Authority
HR
Croatia
Prior art keywords
crystalization
losartan
Prior art date
Application number
HR970565A
Other languages
English (en)
Inventor
Patrick Breen
Erik A Dienemann
Albert D Epstein
Karen A Larson
Michael T Kennedy
Hari Mahadevan
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625804.1A external-priority patent/GB9625804D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP970565A2 publication Critical patent/HRP970565A2/hr
Publication of HRP970565B1 publication Critical patent/HRP970565B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HR970565A 1996-10-29 1997-10-24 Process for the crystalization of losartan HRP970565B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2932696P 1996-10-29 1996-10-29
GBGB9625804.1A GB9625804D0 (en) 1996-12-12 1996-12-12 Process for the crystallization of losartan

Publications (2)

Publication Number Publication Date
HRP970565A2 HRP970565A2 (en) 1998-08-31
HRP970565B1 true HRP970565B1 (en) 2003-02-28

Family

ID=26310606

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970565A HRP970565B1 (en) 1996-10-29 1997-10-24 Process for the crystalization of losartan

Country Status (18)

Country Link
US (1) US5859258A (de)
EP (1) EP0937068B1 (de)
JP (1) JP3249827B2 (de)
CN (1) CN1101393C (de)
AR (1) AR010256A1 (de)
AT (1) ATE214388T1 (de)
AU (1) AU5089898A (de)
BR (1) BR9712390A (de)
CZ (1) CZ291672B6 (de)
DE (1) DE69711068T2 (de)
DK (1) DK0937068T3 (de)
EA (1) EA001046B1 (de)
ES (1) ES2173433T3 (de)
HR (1) HRP970565B1 (de)
PT (1) PT937068E (de)
SK (1) SK282875B6 (de)
TW (1) TW411338B (de)
WO (1) WO1998018787A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226372A (ja) 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
JP2002080354A (ja) * 2000-09-05 2002-03-19 Kao Corp 血圧降下剤組成物
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
SK722003A3 (en) * 2001-05-18 2003-12-02 Aurobindo Pharma Ltd Process for the crystallization of losartan potassium
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
EP1438027A1 (de) * 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
SI1474417T1 (sl) 2002-04-29 2006-08-31 Teva Pharma Postopek za pripravo lozartana in kalijevega lozartana
US20040097568A1 (en) * 2002-07-29 2004-05-20 Dr. Reddy's Laboratories Limited Crystalline form of losartan potassium
ATE369132T1 (de) * 2002-10-17 2007-08-15 Teva Pharma Verfahren zur herstellung von losartan kaliumsalz mit verbesserten fliesseigenschaften
AU2003278422A1 (en) * 2002-10-31 2004-05-25 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
EP1589966B1 (de) * 2003-01-30 2010-11-10 LEK Pharmaceuticals d.d. Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
WO2005066158A2 (en) * 2004-01-06 2005-07-21 Ipca Laboratories Limited An improved process for the synthesis of losartan potassium
EP1776095A1 (de) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und at1-rezeptor-antagonisten
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
ITMI20050551A1 (it) * 2005-04-01 2006-10-02 Dipharma Spa Forma cristallina alfa di losartan potassio
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
WO1993010106A1 (en) * 1991-11-18 1993-05-27 E.I. Du Pont De Nemours And Company Tetrazolylphenylboronic acid intermediates for the synthesis of aii receptor antagonists
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
WO1995017396A1 (en) * 1993-12-23 1995-06-29 Merck & Co., Inc. Polymorphs of losartan and the process for the preparation of form ii of losartan

Also Published As

Publication number Publication date
ES2173433T3 (es) 2002-10-16
US5859258A (en) 1999-01-12
CZ151599A3 (cs) 1999-10-13
EA001046B1 (ru) 2000-08-28
ATE214388T1 (de) 2002-03-15
CN1241186A (zh) 2000-01-12
PT937068E (pt) 2002-07-31
EA199900427A1 (ru) 1999-10-28
SK282875B6 (sk) 2003-01-09
DK0937068T3 (da) 2002-05-21
JP3249827B2 (ja) 2002-01-21
BR9712390A (pt) 1999-08-31
TW411338B (en) 2000-11-11
EP0937068A1 (de) 1999-08-25
SK57099A3 (en) 2000-02-14
DE69711068D1 (de) 2002-04-18
CN1101393C (zh) 2003-02-12
HRP970565A2 (en) 1998-08-31
JP2000504343A (ja) 2000-04-11
AU5089898A (en) 1998-05-22
EP0937068B1 (de) 2002-03-13
WO1998018787A1 (en) 1998-05-07
AR010256A1 (es) 2000-06-07
CZ291672B6 (cs) 2003-04-16
DE69711068T2 (de) 2002-09-12

Similar Documents

Publication Publication Date Title
HRP970565B1 (en) Process for the crystalization of losartan
GB9616573D0 (en) Process
GB9609441D0 (en) Process
EP0880388A4 (de) Veretherungs-hydrierungsprozess
IL119612A0 (en) Method for the production of khalas
HU9600855D0 (en) Process for producing tenidap
IL129868A0 (en) Process for the synthesis of benzothiopenes
GB9602046D0 (en) Process
HUP9901029A3 (en) Method for the production of rdspa alfa1
GB2319771B (en) Process
IL112839A0 (en) Methods for the purification of halofluorocarbons
HUP9904497A3 (en) Method for the production of ivermectin
GB2316403B (en) Process
GB9617658D0 (en) Process
EP0989135A4 (de) Neue phosphinopyrrolidin-vebindungen und ein verfahren zu ihrer herstellung
GB9625804D0 (en) Process for the crystallization of losartan
ZA979066B (en) Process for the synthesis of β-ketonitriles.
IL131765A0 (en) Process for the purification of substituted p-nitrodiphenylethers
EG21037A (en) Process for the synthesis of benzathiophenes
HUP9902584A3 (en) Process for the production of 2h-1-benzopyrans
IL125541A0 (en) Process for the production of 5-hydroxyoxazolidinones
SI0882035T1 (en) Process for the production of 2h-1-benzopyrans
ZA961975B (en) An improved process for the manufacture of 2-isopropyl-4-methyl 6-hydroxypyrimidine
FI102790B1 (fi) Puheentunnistusmenetelmä
GB9613308D0 (en) Process

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090929

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20101025